Aurora crews tackle 2 fires on same property
According to the Aurora Fire Rescue, crews were called to a four-story multifamily residential building near the intersection of North Ursula Street and East 21st Avenue. The area is in the Fitzsimons neighborhood next to the Anschutz Medical Campus.
Initially, crews were called about a small mulch fire. Aurora Fire Rescue said the fire was fully extinguished and crews cleared the call.
Do you recognize these Centennial burglary suspects? Investigators need help
However, about an hour later at 8:45 p.m., Aurora Fire said the building's alarm system detected smoke.
When crews arrived the second time, they saw flames on the exterior of the building. Aurora Fire said the second floor of the building was cleared, and crews put out the flames within minutes. Following an initial investigation, firefighters learned the fire infiltrated the building's exterior walls and burned a 2-foot-by-4-foot section of the first-floor sprinkler room before it was controlled.
The residents were able to return to their units and no injuries were reported.
The second fire is still under investigation, and it is unclear if the two fires are related. Aurora Fire Rescue said the initial mulch fire may have been caused by a stray cigarette or other smoking device.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
05-08-2025
- New York Times
Why Do I Get So Many Headaches During the Summer?
Q: I'm always getting headaches during the summer. Why? And what can I do to prevent them? If you've noticed more pain between your temples as the warmer months tick by, it may not be all in your head. Some studies have suggested that hot or humid weather, bright sunlight and summer-related drops in outdoor air pressure can trigger headaches in some people. Migraine sufferers in particular often report being the most affected, said Dr. Danielle Wilhour, an assistant professor of neurology at the University of Colorado Anschutz Medical Campus. While there isn't anything you can do to change the weather itself, the good news is that experts say there are some steps you can take to thwart the throbbing before it starts. What the Research Suggests It can be challenging for scientists to study how the outdoor world influences headache frequency, in part because everyone's triggers are different, and not everyone is triggered equally. It's also possible that early migraine symptoms are just associated with, rather than caused by, certain weather changes. As a result, the conclusions of relevant studies have been mixed. In one study published in 2017, for instance, researchers found that warm and humid conditions in North Carolina were associated with more migraine-related emergency department visits compared with other weather patterns. In another study, published in 2023, researchers in Japan used a smartphone app to track self-reported headaches among nearly 4,400 adults — mostly women. After comparing that data with local weather patterns, they found that headaches were more common in humid weather, but not in the heat. Want all of The Times? Subscribe.
CBS News
03-08-2025
- CBS News
Aurora Fire Rescue fights back against cancer risks with new screenings, turnout gear
Firefighters in Colorado face a lot of dangers that put them at risk of injury or illness, but one of the more prevalent problems can come from their own gear. Now, Aurora Fire Rescue is taking steps to make sure its crews stay safe while saving others. Firefighters have some of the highest risks for job-related cancer. According to the CDC, they are 9% more likely to be diagnosed with cancer than the average American because of the chemicals that can be released in fires and the chemicals used to protect them from those fires. "The problem with this inner shell is it contains PFAS, and PFAS contributes to firefighter cancer," said Aurora Fire Rescue Assistant Chief Hunter Hackbarth. PFAS stands for per- and polyfluoroalkyl substances, but they're also known as "forever chemicals." They don't break down into the environment readily and include dozens of substances known to cause a variety of health problems. According to the International Association of Fire Fighters, 72% of their members' line-of-duty deaths in 2023 were due to occupational cancer. "We have had two retirees that have passed from cancer. We have other retirees that are managing some cancer issues right now," said Hackbarth. That's why Aurora Fire Rescue is investing in programs to keep its men and women safe. First, they are starting lifespan cancer screenings for their firefighters through a federal government grant, and they are getting new gear free from cancer-causing PFAS. "Which is a single-layer gear, protective outer shell that we wear for medical calls, car accidents, auto extrication, wildland fire and general use compared to our structure, firefighting gear," said Hackbarth. The idea is that since the majority of calls they respond to are not structure fires, they can wear the light gear that doesn't expose them to PFAS like their bunker gear does. They will still have to use and carry their bunker gear, but will use it less often. It's an idea that is a big hit around the firehouse. "They're a lot lighter. They're a lot easier to walk around and breathe," said firefighter Patrick Slama. "In the summer, it will be nice," said firefighter Seidel.
Yahoo
30-06-2025
- Yahoo
Acesis Biomed Secures Patents Advancing Testosterone-Inducing Drug Development
Company milestone aligns with June's Men's Health Month and ongoing capital raising initiative Centennial, Colorado, June 30, 2025 (GLOBE NEWSWIRE) -- Acesis Holdings Corporation ('Acesis Biomed'), a pre-clinical stage biomedical company pioneering oral treatments for metabolic and endocrine disorders linked to low testosterone, today announced a meaningful expansion of its intellectual property portfolio with the granting of two patents supporting the development of its novel treatment for low testosterone. The United States Patent and Trademark Office has issued U.S. Patent No. 12324839, effective June 10, 2025, with a notable 380-day term extension. Additionally, Chinese Patent No. ZL2019800872788 was granted on June 6, 2025, strengthening Acesis's global presence and international protection for its novel drug candidates. The milestone coincides with Men's Health Month, underscoring the company's focus on advancing solutions for hormone-related health conditions. Testosterone deficiency, or low T, affects millions of men globally and is increasingly recognized not only for its impact on energy and libido, but also for its role in serious chronic conditions such as obesity, type 2 diabetes, cardiovascular disease, and diminished quality of life. Despite its prevalence, current treatments often rely on hormone replacement therapies, which may not be suitable for all patients and can carry risks such as infertility. Acesis Biomed is developing a potentially first-in-class platform of oral, mechanism-based treatment designed to stimulate the body's own production of natural testosterone. This approach is designed to address a critical unmet need by potentially offering an alternative to traditional therapies. 'This patent milestone highlights our continued progress and commitment to scientific innovation and strengthens the value of our emerging therapeutic pipeline,' said Costas Karatzas, PhD, Co-founder and CEO of Acesis Biomed. 'Testosterone deficiency remains widely underdiagnosed and an undertreated condition in men. Furthermore, this achievement, especially during Men's Health Month, reaffirms our mission to provide safe, effective novel treatments that improve health outcomes for men worldwide with low T.' With a growing awareness of the risks associated with untreated low T, Acesis Biomed offers both patients and investors a compelling opportunity at the forefront of men's health innovation. Acesis is currently raising capital through a Regulation CF Crowdfunding (RegCF) campaign to support the advancement of its proprietary oral drug candidates. For more details and to join the campaign, visit: About Acesis Biomed Acesis Holdings Corporation ('Acesis Biomed' or the 'Company') is a pre-clinical biomedical company developing a pipeline of oral drug candidates targeting metabolic and endocrine disorders associated with testosterone deficiency (low T). With an initial focus on male hypogonadism, Acesis is committed to improving outcomes across multiple co-morbidities of low-T, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Find out more at Costas N. Karatzas, Ph.D. information(at) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
